Nomura Holdings’s ALX Oncology ALXO Stock Holding History

Nomura Holdings’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-26,424	Closed	-$570K	–	1957
2021 Q4	$570K	Buy	+26,424	New	+$1.14M	﹤0.01%	1438

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Nomura Holdings's ALXO Position: Q1 2022 in Review

Nomura Holdings sold out of ALX Oncology (ALXO) in Q1 2022, closing a stake of 26,424 shares — an estimated $570K sold.

Nomura Holdings first reported a position in ALXO in Q4 2021 and held it in 1 quarter. The position peaked at $570K in Q4 2021. 96 funds tracked by Wall St. Rank hold ALXO as of Q1 2022.

Nomura Holdings reported no remaining ALX Oncology position as of Q1 2022 after selling out during the quarter.
Nomura Holdings sold 26,424 ALX Oncology shares in Q1 2022, an estimated $570K.
Nomura Holdings first reported a position in ALX Oncology in Q4 2021 and held it in 1 quarter.
Nomura Holdings's ALX Oncology position peaked at $570K in Q4 2021.
96 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2022.

Based on Nomura Holdings's 13F filing for Q1 2022, filed 18 May 2022.